LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.
Masafumi Ikeda, Marcus-Alexander Wörns, Mehmet Akce...
https://pubmed.ncbi.nlm.nih.gov/41277677/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-28
4000
Participants Needed
161
Research Sites
N/A
Total Duration
Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.
CONDITIONS
Observational Study Protocol: LIVER-R
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
ICON plc
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 7 years, including baseline and follow-up periods
Participants are observed during routine clinical visits, with data collected from medical records and visits over time.
Data collection at enrollment and every 6 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Masafumi Ikeda, Marcus-Alexander Wörns, Mehmet Akce...
https://pubmed.ncbi.nlm.nih.gov/41277677/AstraZeneca
Lead Sponsor
ICON plc
Collaborating Sponsor